Seqens takeover confirmed

SK Capital Partners has announced that it, Eurazeo and other shareholders in Seqens have entered a formal agreement for it to acquire Seqens. This follows a period of exclusive negotiations and the agreement of the employee representative body. This remains subject to regulatory approval. S

K Capital said that this deal “represents a key investment in an integrated global leader active in pharmaceutical solutions and specialty ingredients, through various complementary business units”. It plans to merge US-based Wavelength Pharmaceuticals with Seqens “to create a global leader in the API and CDMO sectors”.

Separately, Seqens has opened its new 1200 m² cGMP pharmaceutical QC laboratory at its salicylic acid production site in Roussillon, France, with Prime Minister Jean Castex. This was built with the 2003 opening of a €100 million, 10,000 tonnes/year paracetamol production unit in mind. The facility also includes a control room and administrative office area.